Insider buying last 90 days
No open-market insider purchases were filed for BLLN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
BillionToOne's week centers on third-quarter results, raised guidance, and insider stock sales. The company reported revenue of $122.98 million and net profit of $17.39 million for Q3 2026, surpassing earnings and revenue estimates, and raised its full-year revenue outlook after sales rose 47% from a year earlier, driven by growth in prenatal and oncology testing, marking a fifth consecutive quarter of positive GAAP operating income. Stifel Nicolaus maintained a Buy rating with a $145.00 price target following the report. Separately, CTO David Tsao sold 20,000 shares at an average price of $109.24, and CEO Oguzhan Atay and his spouse sold 30,335 Class A shares at prices ranging from $107.3142 to $113.1700, both following option exercises at $2.80 per share.
BLLN closed at $114.95, up 0.9%, sitting above both its 50-day average of $105.80 and 200-day average of $97.16, with the shorter average above the longer one. The GekkoIndex reads 51.2, placing the stock in the Neutral zone. Price stands 33.3% below Gekko Fair Value of $172.27.
The next earnings date falls on 3 March 2027, outside a typical 20-trading-day window. Over the last 30 days, there has been 1 unusual options signal, with put premium of $782,070 against call premium of $313,250. The consensus among 5 analysts rating the stock a Buy stands at a $129 target, implying 12.2% upside from current levels.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
BillionToOne scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Averages disagree
Close $105.15 sits between the 50-day ($106.99) and 200-day ($97.66) averages, or the averages disagree.
See the chart62.2, Accumulation
Reading 62.2 is in the Accumulation zone.
See the GekkoIndex37.4% below
Price is 37.4% below Gekko Fair Value (more than 5% below).
See fair valueLeans bearish
Last 30 days: 2 unusual options signals.
See smart moneyReports in 108 days
Next report Mar 3, 2027, 108 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
BillionToOne closed at $105.15 on Nov 13, 2026, +3.3% over the past year, inside a 52-week range of $61.96 to $150.44.
Use the left and right arrow keys to read daily values.
Put BLLN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
BillionToOne builds molecular diagnostic tests around a platform that counts single strands of DNA, aiming to sharpen how accurately diseases can be detected. Rather than relying on broader estimates, the company's approach focuses on isolating and tallying individual molecules, which underlies its work in prenatal and cancer testing.
Among its offerings is UNITY Complete, a screening test that uses a blood draw from an expectant mother to gauge a fetus's chances of aneuploidies, recessive genetic disorders, and fetal antigen issues without any invasive procedure. On the oncology side, Northstar Select analyzes a patient's blood to detect tumor-related mutations, including deletions, insertions, and single-point changes, while Northstar Response follows how a cancer evolves over time by examining methylation patterns. These tools are aimed at supporting both expectant parents and cancer patients through ongoing clinical monitoring.
Founded in 2016, BillionToOne runs its operations out of Menlo Park, California. The company trades on the NASDAQ exchange under the ticker symbol BLLN.
BillionToOne’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.2, in the Accumulation zone, up 10.2 points over five sessions.
Up 10.2 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 12 | +9.2% | +5.2% | ||
| Accumulation (current zone) | 97 | +2.9% | +5.0% | ||
| Neutral | 128 | −1.0% | −1.0% | ||
| Distribution | 10 | −6.0% | −2.9% | ||
| Selling | 0 | Not available | |||
Average BLLN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
BillionToOne trades 37.4% below Gekko Fair Value of $167.90, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what BillionToOne shares are worth, recalculated every trading day.
$167.90
Gekko Fair Value, Nov 14, 2026
37.4% Undervalued
At the end of Sep 2026 the price was 36.5% below the estimate.
No open-market insider purchases were filed for BillionToOne, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BLLN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BLLN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
BillionToOne has been buying back its own shares.
From company filings.
2signals, 48% of the flagged premium in calls.
Latest: Bullish flow on Nov 14, $418K in unusual premium.
BillionToOne reports on Mar 3, 2027 (108 days away), and beat the EPS estimate in 2 of its last 5 reports.
Mar 3, 2027
108 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.15 est $0.18 | $109.4M est $109.2M | −35.6% |
| May 6, 2026 | $0.34 est $0.03 | $108.4M est $97.14M | +16.3% |
| Mar 4, 2026 | $0.11 est $0.06 | $96.05M est $87.19M | −13.2% |
| Dec 9, 2025 | $0.10 est $0.14 | $83.50M est $82.90M | −0.9% |
| Oct 7, 2025 | −$0.02 est $0.14 | $66.60M est $82.90M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for BillionToOne is $128.29, +22.0% from the last close, from 5 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 5 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Piper Sandler | $130 | +23.6% |
| Nov 5 | Canaccord Genuity | $120 | +14.1% |
| Nov 5 | J.P. Morgan | $135 | +28.4% |
| Nov 5 | Stifel Nicolaus | $145 | +37.9% |
| Nov 5 | Piper Sandler | $140 | +33.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BillionToOne’s market cap is $5.02B, with a P/E ratio of 120.4 and revenue of $436.9M over the last twelve months.
Coverage of BillionToOne this week reads neutral: 0 positive, 3 neutral and 0 negative headlines.
BillionToOne’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| GHGuardant Health | Accumulation | 16.4% below |
| SOLVSolventum | Neutral | 17.0% below |
| BTSGBrightSpring Health Services | Neutral | 11.0% above |
| EHCEncompass Health | Neutral | 14.7% above |
| ENSGEnsign | Neutral | 15.6% above |
A peer links to its own page where one exists.
BillionToOne’s market cap is $5.02B at the Nov 13, 2026 close of $105.15, with 43.27M shares outstanding. The shares trade on a P/E ratio of 120.4.
The consensus analyst 12-month price target for BillionToOne is $128.29, +22.0% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate BillionToOne is undervalued: the Nov 13, 2026 close of $105.15 is 37.4% below Gekko Fair Value of $167.90. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
BillionToOne is expected to report on Mar 3, 2027 (108 days away). Analysts expect earnings of $0.16 per share on revenue of $122.4M. BillionToOne beat the earnings estimate in 2 of its last 5 reports, moving 16.5% on average across the report.
BillionToOne’s 52-week high is $150.44 and its 52-week low is $61.96; it closed at $105.15 on Nov 13, 2026, +3.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in BillionToOne over the last 30 days, with $731K of flagged premium in calls and $782K in puts. The latest, bullish flow, was on Nov 14, 2026 with $418K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.